Pediatric ependymomas: Will molecular biology change patient management?

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 638-642

  Grill, Jacques ^a   Bergthold, Guillaume ^a   Ferreira, Céline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

biomarkers; brain tumor; microarray; mouse models; targeted therapy

Indexed keywords

EPHRIN RECEPTOR B2; NOTCH1 RECEPTOR; TENASCIN;

CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME 1Q; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; EPENDYMOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; EPENDYMOMA; HUMANS; MOLECULAR BIOLOGY; NEOPLASM GRADING;

EID: 80054112861     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834b5310     Document Type: Review

References (23)

1. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8:323-335. (Pubitemid 41443417)
2. Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009; 10:206-207.
3. Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Neg Res Biomed 2011; 10:7.
4. Kilday JP, Rahman R, Dyer S, et al. Pediatric ependymoma: biological perspectives. Mol Cancer Res 2010; 7:765-786.
5. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010; 28:3182-3190.
6. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 2009; 27:1884-1892.
7. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006; 24:5223-5233. (Pubitemid 46631366)
8. Palm T, Figarella-Branger D, Chapon F, et al. Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer 2009; 115:3955-3968.
9. Schneider D, Monoranu CM, Huang B, et al. Pediatric supratentorial ependymomas show more frequent deletions on chromosome 9 than infratentorial ependymomas: a microsatellite analysis. Cancer Genet Cytogenet 2009; 191:90-96.
10. Peyre M, Commo F, Dantas-Barbosa B, et al. Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dualcolor microarray-based gene expression analysis. PLoS One 2010; 5:e12932.
11. Andreiuolo F, Puget S, Peyre M, et al. Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro Oncol 2010; 12:1126-1134.
12. Andreiuolo F, Mauguen A, Kilday J, et al. Tenascin-C is an independant prognostic marker in pediatric ependymoma: an international callaborative study [2010 abstract ISPNO, Vienne]. Neuro Oncol 2010; 12:ii26.
13. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466:632-636.
14. Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 2006; 24:1522-1528. (Pubitemid 46638773)
15. Tabori U, Wong V, Ma J, et al. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 2008; 99:1129-1135.
16. Ridley L, Rahman R, Brundler MA, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 2008; 10:675-689.
17. Koos B, Bender S, Witt H, et al. The transcription factor Evi-1 i overexpressed, promotes proliferation and is prognostically unfavorable in infratentorial ependymomas. Cancer Res 2011; 17:3631-3637.
18. Donson AM, Birks DK, Barton VN, et al. Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 2009; 183:7428-7440.
19. Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymoma and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006; 166:74-81.
20. Rahman R, Osteso-Ibanez T, Hirst RA, et al. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol Cancer Ther 2010; 9:2568-2581.
21. Smith MA, Maris JM, Lock R, et al. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 57:268-274.
22. Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology 2009; 73:1677-1680.
23. Bowers DC, Kucejova B, Margraf L, et al. mTORC1 activation in childhood ependymoma and response to sirolimus. J Neurooncol 2011; 103:797-801.